An mRNA Vaccine Against SARS-CoV-2 – Preliminary Report
Jackson, LA, Anderson, EJ, Rouphael, NG, et al. (2020). N Engl J Med, DOI: 10.1056/NEJMoa2022483 AbstractBackground. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein.Methods. We conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to 55 years of age, who received two vaccinations, 28 days apart, with mRNA-1273 in a dose of 25 μg, 100 μg, or 250 μg. There were 15 participants in each dose group. Results.After the Read More …